基于免疫组化分析ERCC1在乳腺癌组织中的表达及对术后远处转移的作用OA

Objective This study investigated the expression of the DNA repair gene resection and repair of cross-complementary group 1(ERCC1)in breast cancer tissues and its impact on postoperative distant metastasis,aiming to provide insights for prognosis assessment and therapeutic target selection in breast cancer patients.Methods A prospective nested case-control study was conducted using a breast cancer cohort established in 2013 at the Affiliated Hospital of Southwest Medical University.Cases were selected and matched 1:1 with controls based on key treatment parameters including patient age,surgery date,surgical approach,and chemotherapy regimen.Participants were divided into a metastatic group(n=93)and a non-metastatic group(n=93)according to the occurrence of distant metastasis post-surgery.Immunohistochemical analysis assessed ERCC1 expression differences between meta-static and non-metastatic groups.ROC curves were generated using R software to determine optimal cutoff values.Cox proportional haz-ards regression analysis via SPSS software explored ERCC1's role in predicting postoperative metastasis.Results There were statisti-cally significant differences between the two groups of breast cancer patients in progesterone receptor status and lymph node metastasis count(P<0.05),while other clinical pathological characteristics showed no statistical significance(P>0.05).ERCC1 was predomi-nantly localized in the nuclei of breast cancer cells,with positive expression appearing as brownish-yellow granules.Protein expression of ERCC1 was higher in the metastatic group than in the control group(P<0.05).ERCC1 was identified as a risk factor for breast cancer metastasis(HR=1.155,95%CI:1.007～1.323,P=0.039).The optimal cutoff value on the ROC curve was 1.5,dividing patients into high-and low-expression groups.The high-expression group exhibited a 5.327-fold increased risk of metastasis com-pared to the low-expression group(HR=5.327,95%CI:1.894～14.988,P=0.002).Conclusion ERCC1 is a risk factor for postop-erative metastasis in breast cancer patients and may serve as a potential biomarker for prognosis assessment and a therapeutic target.